Q4 2025 Nephros Inc Earnings Call Transcript
Key Points
- Nephros Inc (NEPH) reported a 33% revenue growth in 2025, reaching $18.8 million, marking a significant increase from $14.2 million in 2024.
- The company achieved net income of approximately $1.2 million in 2025, marking its second consecutive year of profitability.
- Nephros Inc (NEPH) remains debt-free with a cash balance of $5.4 million at the end of 2025, indicating strong financial discipline.
- The company has successfully expanded its active customer sites to over 1,680 by the end of 2025, up from just over 1,500 in 2024.
- Nephros Inc (NEPH) has launched new products targeting high-impact applications such as ice machines and drinking fountains, expanding its addressable market beyond traditional patient care.
- Gross margin for the fourth quarter of 2025 decreased to 58% from 64% in the same period of 2024, primarily due to the impact of tariffs.
- The company faced a 15% tariff on goods imported from Italy since April 2025, which was only reduced to 10% in February 2026, creating uncertainty around future margin impacts.
- Research and development expenses increased by 57% in the fourth quarter of 2025 compared to the same period in 2024, due to higher headcount and bonuses.
- Selling, general, and administrative expenses rose by 17% in 2025, driven by increased bonuses and sales commissions, impacting overall profitability.
- The company's net income for the fourth quarter of 2025 was $0.1 million, a decline from $0.3 million in the same period of 2024, reflecting decreased gross margins and increased expenses.
Good afternoon, everyone, and welcome to the Nephros Inc fourth quarter 2025 financial results conference call. (Operator Instructions) Please also note today's event is being recorded.
At this time, I would like to turn the floor over to Kirin Smith, Investor Relations. Please go ahead.
Thank you, Jamie, and good afternoon, everyone. This is Kirin Smith with PCG Advisory. Thank you all for participating in Nephros fourth quarter and fiscal year 2025 conference call. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros.
I encourage you to review Nephros filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward looking statements.
Factors that may affect the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
